91 completed, 53 recruiting, 42 active not recruiting, 30 terminated. 105 Phase 2, 65 Not applicable, 32 Phase 1, 17 Phase 3, 7 Early Phase 1.
Follow Prostate Adenocarcinoma: new trials by email Literature Review of Prostate Adenocarcinoma trials Research Report on Prostate Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Whole Versus Partial Gland Boost During Prostate SBRT Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Not yet recruiting | University of Nebraska | 160 | 2026-12-25 | 2026-11-03 |
| Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy TRUS biopsy - Prostate Cancer, Prostate Adenocarcinoma | Suspended | University of Arizona | 100 | 2026-11-01 | 2025-12-03 | |
| SURPASS: Stereotactic Ultra-hypofractionated Radiotherapy for Post-prostatectomy Patients: Adaptive Salvage SBRT Adaptive stereotactic body radiotherapy (SBRT) - Prostate Adenocarcinoma | Not applicable | Not yet recruiting | NYU Langone Health | 30 | 2026-11-01 | 2026-10-22 |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| Effects of Direct Artery Injection on Prostate Cancer Drug Delivery and Tumor Uptake: Imaging-Based Prediction of Treatment Effectiveness Intraarterial injection of 68Ga-PSMA - Prostate Cancer, Prostate Adenocarcinoma | Not applicable | Not yet recruiting | Lithuanian University of Health Sciences | 10 | 2026-08-01 | 2026-06-18 |
| Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer Radiation therapy - Prostate Adenocarcinoma | Phase 2 | Recruiting | University of California, San Diego | 150 | 2026-07-20 | 2026-08-04 |
| A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer Exercise Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 102 | 2026-07-13 | 2026-10-30 |
| A Study of Lower Dose Radiation Therapy for People With Prostate Cancer MR-guided Stereotactic Body Radiation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2026-05-28 | 2026-06-18 |
| Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy - Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Not applicable | Recruiting | Jonsson Comprehensive Cancer Center | 45 | 2026-05-11 | 2026-05-22 |
| Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) Recurrence-directed therapy (RDT), ELIGARD 22.5mg - Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer | Phase 2 | Recruiting | Ontario Clinical Oncology Group (OCOG) | 162 | 2026-05-06 | 2026-10-13 |
| Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation Flotufolastat F18 PET - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Not yet recruiting | University of California, Irvine | 60 | 2026-05-01 | 2026-05-06 |
| INSPIRE: INnovative SABR for Prostate Cancer All IREland Next generation Stereotactic Ablative Radiotherapy (SABR) - Prostate Adenocarcinoma | Phase 2 | Recruiting | Cancer Trials Ireland | 136 | 2026-04-23 | 2026-07-06 |
| Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response Adaptive radiotherapy using SBRT - Prostate Adenocarcinoma, Iliac Nodal Disease | Not applicable | Recruiting | University Health Network, Toronto | 26 | 2026-04-13 | 2026-10-20 |
| Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18 - Prostatic Neoplasms, Prostate Cancer | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 120 | 2026-02-10 | 2026-02-23 |
| Neoadjuvant Embolization and Cytoreduction in Prostate Cancer Prostatic Artery Embolization - Prostate Adenocarcinoma | Phase 2 | Not yet recruiting | Srinivas Raman | 35 | 2026-02-01 | 2025-11-26 |
| Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy fezolinetant - reference formulation, Placebo - Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 2 | Recruiting | Shehzad Basaria, M.D. | 60 | 2026-01-14 | 2026-08-17 |
| Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement Spot Delete planning for proton therapy, Traditional proton treatment planning system - Prostate Cancer, Prostate Adenocarcinoma | Not applicable | Recruiting | Covenant Health Cancer Center | 500 | 2025-12-15 | 2025-12-18 |
| Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer 4D Low Dose Rate Prostate Brachytherapy, Ultra-hypofractionated Radiotherapy - Prostate Adenocarcinoma | Not applicable | Not yet recruiting | Royal Surrey County Hospital NHS Foundation Trust | 220 | 2025-12-01 | 2025-10-07 |
| Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium - Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 30 | 2025-08-25 | 2026-09-23 |
| Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: - Urothelial Carcinoma, Renal Cancer | Not applicable | Recruiting | Institut Claudius Regaud | 450 | 2025-07-23 | 2026-06-15 |
Showing 20 of 253. Sign in to see all of them.
Prostatic Neoplasms (167) · Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Melanoma (4) · Radiation Injuries (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Transitional Cell (3) · Neoplasm Metastasis (3) · Prostatic Diseases (3) · Sarcoma (3) · Small Cell Lung Carcinoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Uterine Cervical Neoplasms (3) · Adenocarcinoma (2) · Adenocarcinoma Of Esophagus (2)
Neoplasms by Site (174) · Urogenital Diseases (173) · Genital Diseases (172) · Male Urogenital Diseases (171) · Urogenital Neoplasms (170) · Neoplasms (169) · Genital Diseases, Male (168) · Genital Neoplasms, Male (166) · Prostatic Diseases (164) · Pathological Conditions, Signs and Symptoms (18) · Pathologic Processes (9) · Signs and Symptoms (9) · Neoplasms by Histologic Type (8) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8)
Magnetic Resonance Spectroscopy (37) · Specimen Handling (19) · Leuprolide (18) · Radiosurgery (18) · Goserelin (14) · gallium 68 PSMA-11 (13) · enzalutamide (12) · Abiraterone Acetate (11) · Radiation (11) · apalutamide (11) · luprolide acetate gel depot (11) · Androgen Antagonists (10) · Prednisone (10) · Radiotherapy (10) · bicalutamide (10)
M.D. Anderson Cancer Center (13) · Mayo Clinic (13) · Jonsson Comprehensive Cancer Center (12) · University of Washington (11) · National Cancer Institute (NCI) (10) · NRG Oncology (9) · University of California, San Francisco (6) · University of Miami (6) · Memorial Sloan Kettering Cancer Center (5) · Andrei Iagaru (4) · I.M. Sechenov First Moscow State Medical University (4) · Roswell Park Cancer Institute (4) · University of Chicago (4) · Abramson Cancer Center at Penn Medicine (3) · Alessa Therapeutics Inc. (3)
United States (193) · Canada (18) · France (9) · Italy (7) · Spain (6) · United Kingdom (6) · Russia (5) · Belgium (4) · Switzerland (4) · Brazil (3) · Netherlands (3) · South Korea (3) · Turkey (Türkiye) (3) · Australia (2) · China (2)
Amar Kishan (4) · Michael Schweizer (4) · Andrei Iagaru (3) · Christopher Logothetis (3) · Evan Yu (3) · Rahul Aggarwal, MD (3) · Alan C Lee (2) · Alan Pollack, MD, PhD (2) · Ashley E Ross (2) · Carlos E. Vargas, M.D. (2) · David Lee, MD (2) · Hashim Ahmed (2) · Paul Corn (2) · Ronald C Chen (2) · Russell Szmulewitz, MD (2)
PMID 41698328, PMID 31375469, PMID 33602654, PMID 33674398, PMID 34326126, PMID 38421243, PMID 15683820, PMID 16170164, PMID 19171418, PMID 20566236, PMID 20818327, PMID 22366187, PMID 23553848, PMID 23707439, PMID 23856036, PMID 24517338, PMID 25240974, PMID 25513855, PMID 25702876, PMID 25847934, PMID 27084275, PMID 27528718, PMID 27568654, PMID 27591931, PMID 27598804, PMID 28497198, PMID 29027195, PMID 29242398, PMID 29242404, PMID 29595042, PMID 29776373, PMID 29876010, PMID 30630500, PMID 30700328, PMID 30811282, PMID 30920593, PMID 31042111, PMID 31092381, PMID 31400383, PMID 31478089, PMID 31515154, PMID 31629656, PMID 32084522, PMID 32302790, PMID 32314028, PMID 32808077, PMID 32958451, PMID 33885704, PMID 33975579, PMID 34406051
U10CA180868 (8), P30CA015704 (4), P30CA060553 (4), P30CA016672 (3), P30CA138292 (3), P30CA008748 (2), P30CA015083 (2), P30CA016056 (2), P50CA097186 (2), R01CA211150 (2), U01CA062491 (2), U10CA180820 (2), 2018 (1), 5UT2CA244056 (1), N01CM00039 (1)